These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2254100)

  • 41. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone.
    Højris I; Andersen J; Overgaard M; Overgaard J
    Acta Oncol; 2000; 39(3):355-72. PubMed ID: 10987233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials.
    Nielsen HM; Overgaard M; Grau C; Jensen AR; Overgaard J
    Radiother Oncol; 2006 May; 79(2):147-55. PubMed ID: 16647152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence.
    Metz JM; Schultz DJ; Fox K; Glick J; Solin LJ
    Cancer J Sci Am; 1999; 5(2):77-83. PubMed ID: 10198729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group.
    Schmoor C; Bastert G; Dunst J; Bojar H; Christmann D; Unbehaun V; Tümmers G; Bauer W; Sauerbrei W; Schumacher M
    Int J Cancer; 2000 May; 86(3):408-15. PubMed ID: 10760830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
    Schumacher M; Bastert G; Bojar H; Hübner K; Olschewski M; Sauerbrei W; Schmoor C; Beyerle C; Neumann RL; Rauschecker HF
    J Clin Oncol; 1994 Oct; 12(10):2086-93. PubMed ID: 7931478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
    Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
    Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conservative surgery and irradiation (QUART) in the treatment of 243 stage I-II breast cancer patients.
    Gasparini G; Panizzoni GA; Dal Fior S; Germani B; Dall'Antonia F; Segato G; Meli S; Pozza F
    Anticancer Res; 1991; 11(4):1635-40. PubMed ID: 1746920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
    Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
    Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
    J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.